While PR-positive tumors are the most apparent candidates, further investigation is warranted to determine the benefit of this approach in broader subgroups, including patients with obesity-driven disease or mismatch repair–deficient (MMR-d) tumors, which may exhibit partial hormonal responsiveness. The gene discussed is PGR; the disease is Obesity.